Senate Bill Would Expand Medicare Obesity Coverage to More Providers, Add Weight-Loss Drug Benefits
A senate committee must act next: committee consideration.
No action since June 2025
This bill’s path across every version that has carried it.
Reintroduced
Reintroduced from H.R. 4818 (118th), which died when its Congress ended.
H.R. 4818 (118th) →How this policy affects specific groups of people
Read twice and referred to the Committee on Finance.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
Lawmakers have introduced the Treat and Reduce Obesity Act of 2025 to mandate Medicare coverage for FDA-approved obesity medications and visits with specialists. The bill would allow a variety of practitioners, including registered dietitians, to provide intensive behavioral therapy.

President Trump announced a deal to expand Medicare coverage for semaglutide and tirzepatide for weight management. While the administration is using pilot programs, the Treat and Reduce Obesity Act remains the legislative path to permanently codify these benefits and expand counseling access.

A landmark deal with pharmaceutical companies will expand Medicare coverage for weight-loss medications starting in mid-2026. This move aligns with goals of the Treat and Reduce Obesity Act, which seeks to modernize Medicare by removing outdated barriers to comprehensive obesity care.
No votes recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Treat and Reduce Obesity Act of 2025
Analysis generated by AI. Always verify with official sources.